

**TO: COMPANY ANNOUNCEMENTS OFFICE
ASX LIMITED**

DATE: 15 December 2014

Cardia secures expanded patent protection for its bioplastics technology



Cardia Bioplastics Limited (ASX: CNN) has secured patent protection for its Cardia Compostable, Biohybrid™ and PPC-starch resin and finished products from Japan, Australia, New Zealand and China Patent and Trademark Offices. Seven new patents were granted during 2014 for Cardia's unique and innovative bioplastics resin formulations and production processes.

These new patents expand Cardia Bioplastics growing intellectual property portfolio of 11 patent families, with 19 patents so far granted in USA, Australia, China, Japan, New Zealand and South Africa. The patents protect the composition formulation and manufacturing process invented by Cardia's R&D team.

The continual expansion of Cardia's patent portfolio validates Cardia's technical capabilities and unique formulation. With rapid global growth of bioplastics use in diverse product applications, Cardia's patent portfolio capitalizes on the demand of leading brand owners where strong intellectual property position is a key requirement.

Please find attached the media release.

Richard Tegoni

Chairman

Cardia Bioplastics Limited

15 December 2014

For Immediate Release

Cardia secures expanded patent protection for its bioplastics technology

- Cardia expands patent portfolio to nineteen patents granted with forty two more pending registration
- Seven new Cardia Compostable, Biohybrid™ and PPC-starch technology patents granted in Japan, Australia, New Zealand and China in 2014
- Intellectual Property underpins commercially successful Cardia Compostable and Biohybrid™ product ranges
- Cardia Bioplastics' technical differentiation endorsed with patents
- Cardia capitalises on growth of bioplastics with leading brand owners where strong intellectual property position is a key requirement



Yoghurt Containers made from Cardia Biohybrid™ technology, now patent protected

Cardia Bioplastics Limited (ASX: CNN) has secured patent protection for its Cardia Compostable, Biohybrid™ and PPC-starch resin and finished products from Japan, Australia, New Zealand and China Patent and Trademark Offices. Seven new patents were granted during 2014 for Cardia's unique and innovative bioplastics resin formulations and production processes.

These new patents expand Cardia Bioplastics growing intellectual property portfolio of 11 patent families, with 19 patents so far granted in USA, Australia, China, Japan, New Zealand and South Africa. The patents protect the composition formulation and manufacturing process invented by Cardia's R&D team.

On receiving the news, Dr. Frank Glatz, Managing Director of Cardia Bioplastics said, “This marks an important milestone for Cardia Bioplastics. These granted patents protect the intellectual property of the Company and further support the technical differentiation of our globally certified Cardia Compostable and independently validated lower carbon foot print Cardia Biohybrid™ product offering.”

“Cardia is collaborating with leading global brand owners to reduce the environmental impact of their packaging. Cardia’s Biohybrid™ technology enables them to reduce the carbon footprint and the use of less oil in their packaging with an environmental benefit whilst maintaining product performance. Cardia’s strong patent position and freedom to operate is a critical requirement for these large global brand owners.”

Richard Tegoni Cardia Bioplastics Chairman stated, “Protecting Cardia’s intellectual property is a high priority as it supports our businesses long-term growth strategy of creating new Compostable and Biohybrid™ resins that meet the needs of the growing market for resins and finished products.”

The continual expansion of Cardia’s patent portfolio validates Cardia’s technical capabilities and unique formulation. With rapid global growth of bioplastics use in diverse product applications, Cardia’s patent portfolio capitalizes on the demand of leading brand owners where strong intellectual property position is a key requirement.

About Cardia Bioplastics

Cardia Bioplastics Limited (ASX CODE: CNN) develops, manufactures and markets its patented renewable resource-based materials and finished products derived from Cardia’s proprietary technology for the global packaging and plastic products industries. The company holds a strong patent portfolio and its growth is fuelled by the global trend towards sustainable packaging. Established in Australia in 2002, the company Headquarters and Global Application Development Centre is in Melbourne, Australia. Cardia Bioplastics’ Product Development Centre and manufacturing plant for resins is in Nanjing, China. Cardia’s manufacturing plants for film and bag products are in Nanjing, China and São Paulo, Brazil with further offices in Australia, China, USA, Brazil and Malaysia, and a network of leading distributors across the Americas, Asia and Europe.

Cardia Bioplastics is well positioned to benefit from the market shift towards sustainable packaging and organics diversion from landfill programs. Cardia offers customers the choice of using sustainable Cardia Biohybrid™ technology (less oil, lower carbon foot print) or Cardia Compostable technology (delivering certified compostability to international standards) for their packaging or plastic product solutions. The company’s materials are suitable for a broad range of packaging applications, including flexible film, injection moulding, blow moulding, foam, and extrusion applications. For further information visit www.cardiabioplastics.com

Further information:

Dr Frank Glatz
Managing Director
Cardia Bioplastics
+61 400 930 530
f.glatz@cardiabioplastics.com

Nadya Krienke-Becker
Global Head of Marketing
Cardia Bioplastics
+61 414 672 863
n.krienke-becker@cardiabioplastics.com